Progenity Inc
NASDAQ:PROG
Intrinsic Value
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PROG.
Fundamental Analysis
Balance Sheet Decomposition
Progenity Inc
Current Assets | 75m |
Cash & Short-Term Investments | 67.2m |
Other Current Assets | 7.8m |
Non-Current Assets | 11.7m |
PP&E | 5.3m |
Other Non-Current Assets | 6.4m |
Current Liabilities | 46.7m |
Accounts Payable | 5.4m |
Accrued Liabilities | 29m |
Other Current Liabilities | 12.4m |
Non-Current Liabilities | 133.2m |
Long-Term Debt | 126.7m |
Other Non-Current Liabilities | 6.5m |
Earnings Waterfall
Progenity Inc
Revenue
|
1.2m
USD
|
Operating Expenses
|
-107.5m
USD
|
Operating Income
|
-106.3m
USD
|
Other Expenses
|
-122.7m
USD
|
Net Income
|
-229m
USD
|
Free Cash Flow Analysis
Progenity Inc
What is Free Cash Flow?
PROG Profitability Score
Profitability Due Diligence
Progenity Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Progenity Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
PROG Solvency Score
Solvency Due Diligence
Progenity Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Progenity Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PROG Price Targets Summary
Progenity Inc
Ownership
PROG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PROG Price
Progenity Inc
Average Annual Return | -60.21% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -96% |
Market Capitalization | 127.1m USD |
Shares Outstanding | 184 200 000 |
Percentage of Shares Shorted | 14.04% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The firm is engaged in developing and commercializing molecular testing products in the fields of women's health, gastrointestinal health and oral biotherapeutics. The company applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, and Resura Prenatal Test for Monogenic Disease. The firm is also developing its pipeline products, such as Preecludia pre-eclampsia rule-out test, Drug Delivery System (DDS) platform, and Oral Biopharmaceutical Delivery System (OBDS). The company is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.